Apixaban in patients with atrial fibrillation

Cited by (1,002)

Items 301–400 of 1,002

1. Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation
   Irene Savelieva, A. John Camm · 2013 · Clinical Cardiology
2. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation
   Mark J. Alberts, John W. Eikelboom, Graeme J. Hankey · 2012 · The Lancet Neurology
3. Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation
   Khai Ping Ng, Nicola C. Edwards, Gregory Y.H. Lip, John Townend, Charles Joseph Ferro · 2013 · American Journal of Kidney Diseases
4. Stroke Etiology and Thrombus Computed Tomography Characteristics in Patients With Acute Ischemic Stroke
   Nikki Boodt, Kars C.J. Compagne, Bruna Garbugio Dutra, Noor Samuels, Manon L. Tolhuisen, Heitor Castelo Branco Rodrigues Alves, Manon Kappelhof, Geert J. Lycklama à Nijeholt, Henk A. Marquering, Charles B.L.M. Majoie et al. · 2020 · Stroke
5. Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran
   Ann De Smedt, Sylvie De Raedt, Koenraad Nieboer, Jacques De Keyser, Raf Brouns · 2010 · Cerebrovascular Diseases
6. Newer Oral Anticoagulants Should Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism
   Christopher Bull Granger, Luciana Armaganijan · 2012 · Circulation
7. Hemostasis, bleeding and thrombosis in liver disease
   Brisas Flores, Hirsh D. Trivedi, Simon Christopher Robson, Alan Bonder · 2017 · Journal of Translational Science
8. Managing atrial fibrillation in the very elderly patient: challenges and solutions
   Κonstantinos P. Letsas, Nikolaos Karamichalakis, Konstantinos George Vlachos, Stamatis Georgopoulos, Athanasios Bakalakos, Michael Efremidis, Antonios Sideris · 2015 · Vascular Health and Risk Management
9. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials
   Koon‐Hou Mak · 2012 · BMJ Open
10. The perioperative management of new direct oral anticoagulants: a question without answers
    Jordi Castillo, José Antonio De Andrés, Carmen Guiralt Gomar, A. Gómez‐Luque, Francisco Hidalgo, Juan V. Llau, Pilar Sierra, Luis Miguel Torres, Raquel Ferrandis · 2013 · Thrombosis and Haemostasis
11. Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation
    Freddy Del‐Carpio Munoz, Shahyar Michael Gharacholou, Thomas M. Munger, Paul A. Friedman, Samuel J. Asirvatham, Douglas L. Packer, Peter A. Noseworthy · 2015 · The American Journal of Cardiology
12. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation
    Jordanne Feldberg, Param Patel, Ashley Farrell, Sylvia Sivarajahkumar, Karen Cameron, Jennifer Ma, Marisa Battistella · 2018 · Nephrology Dialysis Transplantation
13. Atrial Fibrillation Burden Signature and Near-Term Prediction of Stroke
    Lichy Han, Mariam Askari, Russ Biagio Altman, Susan K. Schmitt, Jun Fan, Jason Bentley, Sanjiv M. Narayan, Mintu P. Turakhia · 2019 · Circulation Cardiovascular Quality and Outcomes
14. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation
    Atul Verma, David H. Birnie, Chenyang Jiang, Hein Heidbüchel, Gerhard Hindricks, Paulus F. Kirchhof, Jeff S. Healey, Yunhe Wang, Nikolaos Dagres, Marc William Deyell et al. · 2025 · New England Journal of Medicine
15. Anticoagulants in atrial fibrillation patients with chronic kidney disease
    Robert G. Hart, John W. Eikelboom, Alistair John Ingram, Charles A. Herzog · 2012 · Nature Reviews Nephrology
16. Assessing the Risk of Bleeding in Patients With Atrial Fibrillation
    Gregory Y.H. Lip, Amitava Banerjee, I. Lagrenade, Deirdre A. Lane, Sophie Taillandier, Laurent Fauchier · 2012 · Circulation Arrhythmia and Electrophysiology
17. The left atrial appendage: from embryology to prevention of thromboembolism
    Giuseppe Patti, Vittorio Pengo, Rossella Marcucci, Plinio Lorenzo Cirillo, Giulia Renda, Francesca Santilli, Paolo Calabrò, Alberto Ranieri De Caterina, Ilaria Cavallari, Elisabetta Ricottini et al. · 2016 · European Heart Journal
18. Ophthalmic regional blocks: management, challenges, and solutions
    Howard D. Palte · 2015 · Local and Regional Anesthesia
19. Cerebrovascular disease
    Marileen L.P. Portegies, Peter J. Koudstaal, M. Arfan Ikram · 2016 · Handbook of clinical neurology
20. Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non–Vitamin K Antagonist Oral Anticoagulants
    Tomas Forslund, Joris J. Komen, Morten Tolstrup Andersen, Björn Wettermark, Mia von Euler, Aukje Kaija Mantel-Teeuwisse, Frieder Braunschweig, Paul Hjemdahl · 2018 · Stroke
21. Laparoscopic cholecystectomy for the various types of gallbladder inflammation: a prospective trial.
    Samuel Eldar, Edmond Sabo, E Nash, Jack Abrahamson, Ibrahim Matter · 1998 · PubMed
22. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta‐analysis
    Kochawan Boonyawat, F. Caron, Ang Li, Chatree Chai‐Adisaksopha, Wendy Lim, Alfonso Iorio, Renato D. Lópes, David A. Garcia, Mark Andrew Crowther · 2017 · Journal of Thrombosis and Haemostasis
23. Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study
    Johan Lyth, Emma Svennberg, Lars Bernfort, Mattias Aronsson, Viveka Frykman, Faris Al‐Khalili, Leif Friberg, Mårten Rosenqvist, Johan Engdahl, Lars‐Åke Levin · 2022 · European Heart Journal
24. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry
    Christian Thomas Ruff, Deepak L. Bhatt, Philippe Gabríel Steg, Bernard John Gersh, Mark J. Alberts, Elaine B. Hoffman, E. Magnus Ohman, Kim Allen Eagle, Gregory Y.H. Lip, Shinya Goto · 2013 · International Journal of Cardiology
25. Associations between Cardioembolic Stroke and Obstructive Sleep Apnea
    Melissa C. Lipford, Kelly D. Flemming, Andrew D. Calvin, Jay N. Mandrekar, Robert D. Brown, Virend Kristen Somers, Sean M. Caples · 2015 · SLEEP
26. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people
    Olivier Hanon, Patrick Assayag, Joël Belmin, Jean‐Philippe Collet, J.P. Émeriau, Laurent Fauchier, Françoise Forette, Patrick Friocourt, Armelle Gentric, Christophe Leclercq et al. · 2013 · Archives of cardiovascular diseases
27. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
    Jan Steffel, Eugene Braunwald · 2011 · European Heart Journal
28. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm
    Piotr P. Ponikowski, Felicita Andreotti, Stefan D. Anker, Gerasimos Filippatos, Shunichi Homma, João Morais, Patrick M. Pullicino, Lars Rasmussen, Francisco R. Marín, Deirdre A. Lane et al. · 2012 · Thrombosis and Haemostasis
29. Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach
    on behalf of Grupo de trabajo de Riesgo vascular de la SEMI, Carmen Suárez Fernández, Francesç Formiga, Miguel Camafort, J.M. Cepeda Rodrigo, Jesús Díez‐Manglano, Antonio Pose Reino, Gregorio Tiberio, José María Mostaza · 2015 · BMC Cardiovascular Disorders
30. Left atrial appendage occlusion: rationale, evidence, devices, and patient selection
    Jonathan Paul Piccini, Horst Sievert, Manesh R. Patel · 2016 · European Heart Journal
31. Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
    Brenda B. Cirincione, Kenneth G. Kowalski, Jace C. Nielsen, Amit Roy, Neelima Thanneer, Wonkyung Byon, Rebecca A. Boyd, Xiaoli Wang, Tarek A. Leil, Frank P. LaCreta et al. · 2018 · CPT Pharmacometrics & Systems Pharmacology
32. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
    Tereza Lanitis, François-Emery Cotté, Anne-Françoise Gaudin, Isabelle Kachaner, Thitima Kongnakorn, Isabelle Durand‐Zaleski · 2014 · Journal of Medical Economics
33. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation
    Adrian Matthew Shields, Gregory Y.H. Lip · 2015 · Journal of Internal Medicine
34. Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation
    Ben Freedman, Bernard J. Gersh, Gregory Y.H. Lip · 2014 · European Heart Journal
35. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study
    Shadi R. Yaghi, Nils Henninger, James A. Giles, Christopher R. Leon Guerrero, Eva A. Mistry, Ava Leigh Liberman, Daniyal Asad, Angela Liu, Muhammad Nagy, Ashutosh Kaushal et al. · 2021 · Journal of Neurology Neurosurgery & Psychiatry
36. New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation
    Jack Ansell · 2012 · Circulation
37. Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials
    Partha Sardar, Saurav Chatterjee, Eyal Herzog, Ramez S. Nairooz, Debabrata Mukherjee, Jonathan L. Halperin · 2014 · Canadian Journal of Cardiology
38. Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options
    Bruce Sheldon Stambler, Leonard Mzee Ngunga · 2015 · International Journal of General Medicine
39. Global Survey of the Frequency of Atrial Fibrillation–Associated Stroke
    Kanjana S. Perera, Thomas Vanassche, Jackie Bosch, Balakumar Swaminathan, Hardi Mundl, Mohana Giruparajah, Miguel Angel Barboza, Martin James O'Donnell, Maia Gómez Schneider, Graeme J. Hankey et al. · 2016 · Stroke
40. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry
    Jean‐Pierre Bassand, Saverio Virdone, Marc Badoz, Freek W.A. Verheugt, A. John Camm, Frank J.S. Cools, Keith A.A. Fox, Samuel Zachary Goldhaber, Shinya Goto, Sylvia K. Haas et al. · 2021 · Blood Advances
41. Management of Atrial Fibrillation in Critically Ill Patients
    Mattia Arrigo, Dominique Béttex, Alain Rudiger · 2014 · Critical Care Research and Practice
42. Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry
    Benjamin Adam Steinberg, Rosalia G Blanco, Donna M Ollis, Sunghee Kim, DaJuanicia N. Holmes, Peter Russell Kowey, Gregg C. Fonarow, Jack Ansell, Bernard John Gersh, Alan S. Go et al. · 2014 · American Heart Journal
43. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation
    Jordan K. Schaefer, Robert D. McBane, Waldemar E. Wysokiński · 2015 · Annals of Hematology
44. Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
    Roger E. G. Schutgens, Víctor Jiménez‐Yuste, Miguel Antonio Escobar, Anna Falanga, Bruna Gigante, Robert Klamroth, Riitta Lassila, Frank W.G. Leebeek, Michael Makris, Tarek M. Owaidah et al. · 2023 · HemaSphere
45. Intracranial Hemorrhage and Novel Anticoagulants for Atrial Fibrillation: What Have We Learned?
    Graeme J. Hankey · 2014 · Current Cardiology Reports
46. New oral anticoagulants: a practical guide for physicians
    Rocío Hinojar, Jose Julio Jiménez-Natcher, Covadonga Fernández‐Golfín, José Luis Zamorano · 2015 · European Heart Journal - Cardiovascular Pharmacotherapy
47. Dissection of Cervical and Cerebral Arteries
    Stefan T. Engelter, Christopher Traenka, Philippe A. Lyrer · 2017 · Current Neurology and Neuroscience Reports
48. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta‐Analysis
    Larisa G. Tereshchenko, Charles A. Henrikson, Joaquin E. Cigarroa, Jonathan S. Steinberg · 2016 · Journal of the American Heart Association
49. Practical Guide on Left Atrial Appendage Closure for the Non-implanting Physician. An International Consensus Paper
    Tatjana Potpara, Marek Grygier, Karl Georg Hæusler, Jens Erik Nielsen‐Kudsk, Sérgio Luis Berti, Simonetta Genovesi, Éloi Marijon, Serge Bovéda, Apostolos Tzikas, Giuseppe Boriani et al. · 2024 · EP Europace
50. Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic study
    Xavier Delavenne, Patrick Mismetti, Thierry Basset · 2013 · Journal of Pharmaceutical and Biomedical Analysis
51. Meta-Analysis of the Influence of Chronic Kidney Disease on the Risk of Thromboembolism Among Patients With Nonvalvular Atrial Fibrillation
    Rui Andre Providencia, Éloi Marijon, Serge Bovéda, Sérgio Barra, Kumar Narayanan, Jean‐Yves Le Heuzey, Bernard John Gersh, Lino Manuel Martins Gonçalves · 2014 · The American Journal of Cardiology
52. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials
    Thomas Vanassche, Jack Hirsh, Jeffrey S. Ginsberg, John W. Eikelboom · 2014 · Thrombosis and Haemostasis
53. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
    Kevin L. Thomas, Larry R. Jackson, Peter J. Shrader, Jack Ansell, Gregg C. Fonarow, Bernard John Gersh, Peter Russell Kowey, Kenneth W. Mahaffey, Daniel E. Singer, Laine Elliott Thomas et al. · 2017 · Journal of the American Heart Association
54. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial
    on behalf of the APACHE-AF investigators, Koen M. van Nieuwenhuizen, H. Bart van der Worp, Ale Algra, Laurens Jaap Kappelle, Gabriël J.E. Rinkel, Isabelle C. Van Gelder, Roger E. G. Schutgens, Catharina J.M. Klijn · 2015 · Trials
55. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study
    Martin James O'Donnell, John W. Eikelboom, Salim Yusuf, Hans‐Christoph Diener, Robert G. Hart, Eric Edward Smith, David J. Gladstone, Mukul Sharma, Rafael Dias, Greg Flaker et al. · 2016 · American Heart Journal
56. Epidemiology and Primary Prevention of Stroke
    Karen L. Furie · 2020 · CONTINUUM Lifelong Learning in Neurology
57. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients
    Ariel Dogliotti, Ernesto Paolasso, Robert Patrick Giugliano · 2013 · Heart
58. Systematic review with meta‐analysis: the risk of major gastrointestinal bleeding with non‐vitamin K antagonist oral anticoagulants
    Daniel Caldeira, Márcio Barra, A. Ferreira, A. Rocha, Abrahão Augusto, Fausto José Pinto, João N. Costa, Joaquim José Ferreira · 2015 · Alimentary Pharmacology & Therapeutics
59. Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions
    Luigi Di Biase · 2016 · Journal of the American Heart Association
60. Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease
    Víctor J. Del Brutto, Seemant Chaturvedi, Hans‐Christoph Diener, José G. Romano, Ralph L. Sacco · 2019 · Journal of the American College of Cardiology
61. Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source
    Roland C. Veltkamp, Lesly A. Pearce, Eleni Korompoki, Mukul Sharma, Scott Eric Kasner, Danilo Toni, Sebastián F. Ameriso, Hardi Mundl, Turgut Tatlisumak, Graeme J. Hankey et al. · 2020 · JAMA Neurology
62. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care
    Richard F. Hobbs, Clare J Taylor, Geert Jan Geersing, Frans Hendrik Rutten, Judith Rixt Brouwer, on behalf of the European Primary Care Cardiovascular Society (EPCCS) SPAF working group · 2015 · European Journal of Preventive Cardiology
63. Population-based study of acute- and long-term care costs after stroke in patients with AF
    R. Luengo-Fernandez, G. Yiin, A. Gray, P. Rothwell · 2012 · International Journal of Stroke
64. Apixaban in Patients with Atrial Fibrillation
    A.A. Rabinstein · 2011 · Yearbook of Neurology and Neurosurgery
65. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
    Karsten Bruins Slot, Eivind Berge · 2018 · Cochrane Database of Systematic Reviews
66. The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage
    Jamil R. Dibu, Jonathan M. Weimer, Christine L. Ahrens, Edward M. Manno, Jennifer Ann Frontera · 2015 · Neurocritical Care
67. Atrial Cardiopathy in the Absence of Atrial Fibrillation Increases Risk of Ischemic Stroke, Incident Atrial Fibrillation, and Mortality and Improves Stroke Risk Prediction
    Jodi D. Edwards, Jeff S. Healey, Jiming Fang, Kathy Yip, David J. Gladstone · 2020 · Journal of the American Heart Association
68. Updated guidelines on outpatient anticoagulation.
    Patricia R. Wigle, Bradley E. Hein, Hanna E. Bloomfield, Matthew R. Tubb, Michael Doherty · 2013 · PubMed
69. Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial
    Maria Cecilia Bahit, Renato D. Lópes, DANIEL M. WOJDYLA, Stefan Hans Hohnloser, John Hunter Alexander, Basil S. Lewis, Philip E. Aylward, Freek W.A. Verheugt, Mátyás Keltai, Rafael Díaz et al. · 2013 · International Journal of Cardiology
70. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera
    Håkon Reikvam, Ramon Velasquez Tiu · 2011 · Leukemia
71. Safety of new oral anticoagulant drugs: a perspective
    Juan Antonio Vilchez, Pilar Gallego, Gregory Y.H. Lip · 2013 · Therapeutic Advances in Drug Safety
72. The pharmacology of novel oral anticoagulants
    Tracy A. DeWald, Richard Clinton Becker · 2013 · Journal of Thrombosis and Thrombolysis
73. Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats
    Donglu Zhang, Charles E. Frost, Kan He, A. David Rodrigues, Xiaoli Wang, Lifei Wang, Theunis C. Goosen, William Griffith Humphreys · 2013 · Drug Metabolism and Disposition
74. 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter
    Paul A. Heidenreich, Penelope Solis, N.A. Mark Estes, Gregg C. Fonarow, Corrine Y. Jurgens, Joseph Edward Marine, David D. McManus, Robert L. McNamara · 2016 · Circulation Cardiovascular Quality and Outcomes
75. Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)
    Pavel P. Osmancik, Petr Toušek, Dalibor Heřman, Petr Neužil, Pavel Hála, Josef Šťásek, Luděk Haman, Petr Kala, Martin Poloczek, Marian Branny et al. · 2016 · American Heart Journal
76. Antithrombotic therapy in diabetes: which, when, and for how long?
    Ramzi Ajjan, Noppadol Kietsiriroje, Lina Badimón, Gemma Vilahur, Diana Adrienne Gorog, Dominick Joseph Angiolillo, David Russell, Bianca Rocca, Robert F. Storey · 2021 · European Heart Journal
77. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature
    Cecilia Becattini, Maria Cristina Vedovati, Giancarlo Agnelli · 2012 · Thrombosis Research
78. Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation
    Amy Tawfik, JOANNA M. BIELECKI, Murray Dale Krahn, Paul Dorian, Jeffrey S. Hoch, Heather Shirley Boon, Don Husereau, Petros Pechlivanoglou · 2016 · Clinical Pharmacology Advances and Applications
79. Postdischarge Bleeding After Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction
    Javier Alfonso Valle, Susan M. Shetterly, Thomas M. Maddox, P. Michael Ho, Steven M. Bradley, Amneet Sandhu, David J. Magid, Thomas T. Tsai · 2016 · Circulation Cardiovascular Interventions
80. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms
    Jean‐Christophe Ianotto, Marie‐Anne Couturier, Hubert Galinat, Dominique Mottier, Christian Berthou, Gaëlle Guillerm, Éric Lippert, Aurélien Delluc · 2017 · International Journal of Hematology
81. Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study
    Brigitte Pegourié, Lionel Karlin, Lotfi Benboubker, Frédérique Orsini‐Piocelle, Mourad Tiab, Sophie Auger‐Quittet, Philippe Rodon, Bruno Royer, Xavier P Leleu, Benoît Bareau et al. · 2019 · American Journal of Hematology
82. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation
    Alexander Philipp Benz, Stefan Hans Hohnloser, John W. Eikelboom, Anthony Carnicelli, Robert Patrick Giugliano, Christopher Bull Granger, Josephine Harrington, Ziad Hijazi, David A. Morrow, Manesh R. Patel et al. · 2023 · European Heart Journal
83. Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care
    Markus Gulilat, ANTHONY S.L. TANG, Steven E. Gryn, Peter Leong‐Sit, Allan Cameron Skanes, Jeffrey Alfonsi, George K. Dresser, Sara L. Henderson, Rhiannon V. Rose, Daniel J. Lizotte et al. · 2017 · Canadian Journal of Cardiology
84. Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis
    Daniel Caldeira, A Nunes-Ferreira, Raquel Olmedo Rodrigues, Eunice Vicente, Fausto José Pinto, Joaquim José Ferreira · 2018 · Archives of Gerontology and Geriatrics
85. Atrial Fibrillation
    A. John Camm, Irina Savelieva, Siew Yen Ho, Bruce D. Lindsay, Stanley Nattel, Kaori Shinagawa · 2009 · Elsevier eBooks
86. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
    Danielle Clarkesmith, Helen M. Pattison, Deirdre A. Lane · 2013 · Cochrane Database of Systematic Reviews
87. Extended treatment of venous thromboembolism: a systematic review and network meta-analysis
    Kang-Ling Wang, Nick van Es, Chris G Cameron, Lana A. Castellucci, Harry Roger Buller, Marc Carrier · 2018 · Heart
88. Stability‐indicating RP‐HPLC method development and validation for determination of nine impurities in apixaban tablet dosage forms. Robustness study by quality by design approach
    Velusamy B. Subramanian, Naresh Kumar Katari, Thirupathi Dongala, Sreekantha Babu Jonnalagadda · 2019 · Biomedical Chromatography
89. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
    Charles E. Frost, Andrew Shenker, Mohit D. Gandhi, Janice M. Pursley, Yu Chen Barrett, Jessie J.J. Wang, Donglu Zhang, Wonkyung Byon, Rebecca A. Boyd, Frank P. LaCreta · 2014 · British Journal of Clinical Pharmacology
90. How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?
    Rajiv Sankaranarayanan, Graeme J. Kirkwood, Rajaverma Visweswariah, David J. Fox · 2015 · Current Cardiology Reviews
91. Risk Of Gastrointestinal Bleeding Increases With Combinations Of Antithrombotic Agents And Patient Age.
    N. Abraham, P. Noseworthy, J. Inselman, J. Herrin, Xiao-Xi Yao, L. Sangaralingham, Gabriella Cornish, Che G. Ngufor, N. Shah · 2020 · Clinical Gastroenterology and Hepatology
92. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial
    Roland C. Veltkamp, Eleni Korompoki, Kirsten Harvey, Emily R. Harvey, Cornelia Fießler, Uwe Malzahn, Viktoria Rücker, Joan Montaner, Valeria Caso, Igor Sibon et al. · 2025 · The Lancet
93. Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients
    Masato Kaneko, Takahiko Tanigawa, Kensei Hashizume, Mariko Kajikawa, Masahiro Tajiri, Wolfgang Mueck · 2013 · Drug Metabolism and Pharmacokinetics
94. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study
    Laurent Fauchier, Adeline Samson, Gwendoline Chaize, Anne-Françoise Gaudin, Alexandre Vainchtock, Cécile Bailly, François-Emery Cotté · 2015 · Open Heart
95. D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy
    Agneta Siegbahn, Jonas Oldgren, Ulrika Andersson, Michael D. Ezekowitz, Paul A. Reilly, Stuart J. Connolly, Salim Yusuf, Lars C. Wallentin, John W. Eikelboom · 2016 · Thrombosis and Haemostasis
96. 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter
    Paul A. Heidenreich, Penelope Solis, N.A. Mark Estes, Gregg C. Fonarow, Corrine Y. Jurgens, Joseph Edward Marine, David D. McManus, Robert L. McNamara · 2016 · Journal of the American College of Cardiology
97. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012
    Paul L. Hess, Michael J. Mirro, Hans‐Christoph Diener, John W. Eikelboom, Sana M. Al‐Khatib, Elaine M. Hylek, Hayden Barry Bosworth, Bernard John Gersh, Daniel E. Singer, Greg Flaker et al. · 2014 · American Heart Journal
98. Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey
    Tatjana Potpara, Gheorghe‐Andrei Dan, Elina Trendafilova, Artan Goda, Zumreta Kušljugić, Šime Manola, Ljilja Musić, R. Musetescu, Elisabeta Bădilă, Gorana P. Mitic et al. · 2016 · Scientific Reports
99. Underutilization of Ambulatory ECG Monitoring After Stroke and Transient Ischemic Attack
    Jodi D. Edwards, Moira K. Kapral, Jiming Fang, Gustavo Saposnik, David J. Gladstone · 2016 · Stroke
100. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke
     Patrick Sulzgruber, Sven Waßmann, Anne Grete Semb, Wolfram Doehner, Petr Widimský, Thomas Gremmel, Juan Carlos Kaski, Gianluigi Savarese, Giuseppe M.C. Rosano, Claudio Borghi et al. · 2019 · European Heart Journal - Cardiovascular Pharmacotherapy